As a first-line treatment, Nivo-Ipi combination therapy is extensively utilized for advanced NSCLC in patients without targetable genetic alterations in the epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK). This evidence concerns the gene EGFR and non-small cell lung carcinoma.